Description
Product details
GEFISTERIS 250 is a premium pharmaceutical formulation containing Gefitinib 250mg, a breakthrough targeted therapy medication manufactured by Steris Healthcare. This innovative oral medication represents a significant advancement in the treatment of non-small cell lung cancer (NSCLC), offering patients a precise, scientifically-designed approach to combating one of the world's most challenging malignancies. GEFISTERIS 250 is specifically engineered to target the underlying molecular mechanisms that drive certain types of lung cancer, providing hope and extended survival for patients who carry specific genetic mutations. As a tyrosine kinase inhibitor, GEFISTERIS 250 works at the cellular level to interrupt the signals that tell cancer cells to grow and divide. This targeted approach differs fundamentally from traditional chemotherapy, which affects both healthy and cancerous cells. By focusing specifically on cancer cells with epidermal growth factor receptor (EGFR) mutations, GEFISTERIS 250 offers a more refined treatment strategy with potentially fewer systemic side effects and improved quality of life during treatment. Understanding Gefitinib 250mg: The Science Behind GEFISTERIS 250 Gefitinib 250mg, the active pharmaceutical ingredient in GEFISTERIS 250, belongs to a revolutionary class of medications known as epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). The development of this medication marked a paradigm shift in oncology, moving from one-size-fits-all chemotherapy approaches to personalized, mutation-specific treatments. The EGFR protein is found on the surface of cells and plays a crucial role in cell growth and division. In normal cells, EGFR activation is carefully regulated. However, in certain lung cancers, mutations in the EGFR gene cause the receptor to remain constantly active, sending continuous signals for the cell to grow, divide, and survive—leading to uncontrolled cancer growth. GEFISTERIS 250 works by blocking the tyrosine kinase activity of the mutated EGFR protein, effectively turning off the growth signal and causing cancer cells to stop proliferating and eventually die. This precision targeting is what makes GEFISTERIS 250 particularly effective for patients whose tumors harbor activating EGFR mutations, particularly the common exon 19 deletions or exon 21 L858R substitution mutations. Before initiating treatment with GEFISTERIS 250, patients undergo molecular testing to confirm the presence of these mutations, ensuring that the therapy is appropriately matched to their specific cancer biology. Primary Uses and Indications of GEFISTERIS 250 GEFISTERIS 250 is primarily indicated for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors have specific EGFR mutations. The medication is approved for both first-line treatment in newly diagnosed patients and for those whose disease has progressed after platinum-based chemotherapy. First-Line Treatment: When EGFR mutations are detected in treatment-naïve patients, GEFISTERIS 250 offers an excellent first-line option, often providing superior progression-free survival compared to traditional chemotherapy regimens. Patients starting with targeted therapy typically experience better tolerability and quality of life during initial treatment phases. Second-Line and Beyond: For patients whose cancer has progressed after chemotherapy, GEFISTERIS 250 provides an effective alternative treatment option, particularly when EGFR mutation testing was not performed initially or when the mutation status was unknown at the time of first treatment. The medication is taken orally as a once-daily tablet, offering significant convenience compared to intravenous chemotherapy that requires hospital visits and lengthy infusion times. This oral administration allows patients to maintain greater independence and normalcy in their daily lives while receiving effective cancer treatment. Key Benefits of GEFISTERIS 250 1. Targeted Cancer Fighting Action The primary benefit of GEFISTERIS 250 lies in its precision targeting mechanism. Unlike conventional chemotherapy that attacks all rapidly dividing cells in the body, GEFISTERIS 250 specifically targets cancer cells bearing EGFR mutations. This selective action means that healthy cells are largely spared, resulting in a more favorable side effect profile and better preservation of normal bodily functions during treatment. 2. Superior Efficacy in EGFR-Mutant NSCLC Clinical trials have consistently demonstrated that GEFISTERIS 250 and other EGFR-TKIs provide superior progression-free survival compared to chemotherapy in patients with EGFR-mutant NSCLC. Response rates typically range from 60-80% in appropriate patient populations, with many patients experiencing significant tumor shrinkage and symptomatic improvement within weeks of starting treatment. 3. Improved Quality of Life Patients taking GEFISTERIS 250 often report better quality of life compared to those receiving traditional chemotherapy. The medication's targeted nature results in fewer debilitating side effects such as severe nausea, hair loss, and profound fatigue. Many patients can continue working, traveling, and engaging in normal daily activities while on treatment. 4. Convenient Oral Administration GEFISTERIS 250's once-daily oral dosing eliminates the need for frequent hospital visits for intravenous chemotherapy infusions. Patients take one tablet daily at home, providing tremendous convenience and reducing the burden of treatment. This ease of administration contributes significantly to treatment adherence and patient satisfaction. 5. Rapid Symptom Relief Many patients experience rapid improvement in cancer-related symptoms such as cough, shortness of breath, chest pain, and fatigue within the first few weeks of GEFISTERIS 250 treatment. This quick symptomatic relief can dramatically improve quality of life even before significant tumor shrinkage is visible on imaging studies. 6. Extended Survival Benefits Long-term data demonstrates that appropriate use of EGFR-TKIs like GEFISTERIS 250 contributes to extended overall survival in patients with EGFR-mutant lung cancer. When used as part of a comprehensive treatment strategy, including potential sequential therapies after progression, patients can achieve survival times that were unimaginable before the advent of targeted therapies. 7. Manageable Side Effect Profile While GEFISTERIS 250 does cause side effects, they are generally more manageable than those associated with traditional chemotherapy. Most side effects can be effectively controlled with supportive medications, dose modifications, or temporary treatment interruptions, allowing patients to continue benefiting from therapy. 8. Quality Manufacturing by Steris Healthcare GEFISTERIS 250 benefits from Steris Healthcare's commitment to pharmaceutical excellence. Each tablet undergoes rigorous quality testing to ensure consistent potency, purity, and bioavailability. This quality assurance means patients receive reliable, effective medication with every dose. Side Effects of GEFISTERIS 250 (Gefitinib 250mg) While GEFISTERIS 250 offers significant therapeutic benefits, patients should be aware of potential side effects. Understanding these effects enables early recognition and appropriate management. Common Side Effects (Affecting 20% or More of Patients): Skin Reactions: The most characteristic side effect of GEFISTERIS 250 is an acne-like rash, typically appearing on the face, chest, and back within the first few weeks of treatment. This rash, while cosmetically concerning for some patients, actually correlates with better treatment response. The rash can be managed with topical antibiotics, moisturizers, and sun protection. In severe cases, temporary dose reduction may be necessary. Diarrhea: Approximately 50-60% of patients experience diarrhea of varying severity. Mild diarrhea can often be managed with dietary modifications and over-the-counter anti-diarrheal medications like loperamide. Patients should stay well-hydrated and contact their healthcare provider if diarrhea becomes severe or persistent, as dose adjustments may be needed. Nail Changes: Some patients develop paronychia (nail bed inflammation) or other nail abnormalities. Proper nail care, avoiding trauma to the nail beds, and wearing protective gloves during housework can help minimize these effects. Dry Skin: Many patients experience skin dryness and itching. Regular use of fragrance-free moisturizers, gentle cleansers, and avoidance of hot showers can help manage these symptoms. Mouth Sores: Oral mucositis or stomatitis can develop in some patients. Good oral hygiene, avoiding spicy or acidic foods, and using alcohol-free mouthwashes can provide relief. Less Common but Serious Side Effects: Interstitial Lung Disease (ILD): While rare (1-2% of patients), ILD is the most serious potential side effect of GEFISTERIS 250. Symptoms include sudden onset or worsening of respiratory symptoms such as difficulty breathing, cough, or fever. This requires immediate medical attention and usually necessitates permanent discontinuation of the medication. Liver Function Abnormalities: Elevated liver enzymes can occur, requiring regular monitoring through blood tests. Most cases are asymptomatic and reversible with dose modification or temporary discontinuation. Eye Problems: Dry eyes, corneal erosion, or other ocular issues may develop. Regular use of lubricating eye drops and ophthalmological evaluation when symptoms occur can prevent serious complications. Gastrointestinal Perforation: Though rare, serious gastrointestinal complications including perforation can occur, particularly in patients with underlying GI conditions. Management Strategies: Most side effects can be effectively managed through: Proactive supportive care and prophylactic measures Dose modifications (reduction to 250mg every other day in some cases) Temporary treatment interruptions allowing recovery Symptomatic treatment with appropriate medications Patient education about early recognition and reporting of symptoms Patients should maintain open communication with their healthcare team, reporting any new or worsening symptoms promptly. Regular monitoring through clinical visits and laboratory testing helps identify and address side effects before they become serious. Dosage and Administration Guidelines The standard dose of GEFISTERIS 250 is one 250mg tablet taken orally once daily, with or without food. The tablet should be swallowed whole with water and should not be crushed or chewed. If a dose is missed and it's been less than 12 hours since the scheduled time, patients should take the missed dose. If more than 12 hours have passed, skip the missed dose and resume the regular schedule—never double up on doses. Treatment continues until disease progression or unacceptable toxicity occurs. Some patients remain on GEFISTERIS 250 for months or even years if they continue to benefit without prohibitive side effects. Dose modifications may be necessary based on individual tolerance, typically reducing the frequency to every other day rather than lowering the individual dose. Precautions and Important Considerations Patients taking GEFISTERIS 250 should be aware of several important precautions. The medication can cause harm to developing fetuses, so women of childbearing potential must use effective contraception during treatment and for at least two weeks after the last dose. Breastfeeding should be avoided during treatment and for two weeks after completion. GEFISTERIS 250 can interact with medications that affect stomach acid, including proton pump inhibitors and H2-receptor antagonists. If antacids are needed, they should be taken several hours apart from GEFISTERIS 250. The medication may also interact with certain other drugs metabolized by the liver, so patients should inform their healthcare provider about all medications, supplements, and herbal products they're taking. Regular monitoring is essential during GEFISTERIS 250 treatment, including periodic liver function tests, pulmonary symptom assessment, and clinical evaluation for skin and other toxicities. Patients should avoid prolonged sun exposure and use high-SPF sunscreen, as the medication can increase photosensitivity. Conclusion GEFISTERIS 250 represents a transformative treatment option for patients with EGFR-mutant non-small cell lung cancer, offering targeted, effective therapy with a manageable side effect profile. Manufactured by Steris Healthcare with unwavering commitment to quality and patient outcomes, GEFISTERIS 250 delivers Gefitinib 250mg in a formulation designed for optimal bioavailability and consistent therapeutic effect. The medication's precision targeting of cancer-driving mutations, combined with convenient oral administration and generally tolerable side effects, makes GEFISTERIS 250 an excellent choice for eligible patients. While side effects do occur and require monitoring and management, the potential benefits—including tumor response, symptom improvement, extended progression-free survival, and enhanced quality of life—often significantly outweigh the risks for appropriately selected patients. Success with GEFISTERIS 250 requires partnership between patients and their healthcare teams. Molecular testing to confirm EGFR mutation status before treatment, adherence to the prescribed regimen, proactive management of side effects, and regular monitoring all contribute to optimal outcomes. For many patients with EGFR-mutant lung cancer, GEFISTERIS 250 offers not just treatment, but genuine hope for extended, quality life. As personalized medicine continues to evolve, medications like GEFISTERIS 250 exemplify the power of matching treatments to individual tumor characteristics. Steris Healthcare's commitment to delivering this advanced therapy with assured quality and accessibility ensures that more patients can benefit from the remarkable advances in targeted cancer treatment that Gefitinib 250mg represents.
